1. English
  2. English

MACVIA-ARIA Sentinel Network for rhinitis

AIRWAYS ICPs (Action Plan B3, EIP on AHA) develops multisectoral care pathways (ICPs) for rhinitis and its multimorbidities, implementing emerging technologies for individualised and predictive medicine using an ICT tool available in 15 EU countries and already tested in 5,000 users of all ages. This smartphone-based tool allows the assessment of rhinitis control and uses a clinical decision support system. 1- MASK (MACVIA-ARIA Sentinel network) ALLERGY DIARY: MASK-rhinitis is a simple ICT tool to implement care pathways for allergic rhinitis from patients to health care providers using a common language for patients, health care providers and social carers. This is based on the assessment of the control of allergic rhinitis by a visual analogue scale on and App and a tablet. MASK-rhinitis will allow (i) the patients to screen for allergic disease, (ii) the pharmacists, to guide them in the prescription of OTC medications and direct the uncontrolled patients to physicians, (iii) the primary care physician, to prescribe appropriate treatment and to follow-up with the patient according to the physician’s instructions (CDSS) and assessment of control, (iv) the specialist and outpatient clinics in allergology, if there is failure to gain control by the primary physician and (v) assess work productivity. Moreover, EQ-5D is included in the tool allowing MAFEIP. MASK-rhinitis is important for establishing care pathways across the life cycle, stratify patients with severe uncontrolled rhinitis and to perform clinical trials. 3- CLINICAL DECISION SUPPORT SYSTEM: The selection of pharmacotherapy for patients with allergic rhinitis depends on several factors, including age, prominent symptoms, symptom severity, control of allergic rhinitis, patient preferences and cost. Allergen exposure and resulting symptoms vary and treatment adjustment is required. Clinical decision support systems (CDSS) are beneficial for the assessment of disease control if based on the best evidence and algorithms to aid patients and health care professionals to jointly determine the treatment and its step-up or step-down strategy depending on AR control. MASK Allergy Diary will include a CDSS (End 2016) with an algorithm developed by consensus (Bousquet J et al, J Allergy Clin Immunol, 2016, in press). The tool belongs to the Région Occitanie (France)
Background
Geographical scope: 
International level
Region involved:
Countries involved:
Organisation
Organisation name: 
MACVIA-France
Organisation address: 
MACVIA-France (contre les Maladies Chroniques pour un VIeillissent Actif en France. Fighting chronic diseases for active and healthy ageing in France), Fondation Partenariale FMC VIA-LR, Université Montpellier, Boulevard Henri IV, 34000- Montpellier, France, +33-611-42-88-47 ...
Kind of organisation: 
Hospitals
Primary care centres
Specialised physicians
General practioners
Pharmacists
Nurses
Day care centres
Home care centres
Nursing homes
Informal caregivers
Housing organisations
Private companies
Micro-sized industry
Small-sized industry
Medium-sized industry
Research centres
Academia
NGOs
International/European public authorities
National public authorities
Regional public authorities
Local public authorities
Advocacy organisations patients/users
Advocacy organisations physicians
Viability
Time for deployment: 
Less than a year
Preparation of implementation: 
The App is freely available in Apps Stores and Android of 15 EU countries (ALLERGY DIARY), Mexico and Australia. It will be launched in 7 countries including Brazil, Canada, the US before the end of the year. It is proposed to the Reference Sites for deployment.
Investment per citizen / service user / patient: 
Between 100 – 1.000 EUR per targeted citizen / patient
Cost calculation: 
The total cost to develop the practice was less than 2 M€. It is now freely available and the number of users is illimited. We roughly need 500 k€ to maintain the practice yearly.
Evidence of practice: 
Documented evidence. Evidence is based on systematic qualitative and quantitative studies
Evidence creation: 
Aims: To assess in a feasibility study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by Allergy Diary could be identified and (iii) information gathered by this study could suggest novel...
Maturity level: 
The practice is “on the market” and integrated in routine use. There is proven market impact, in terms of job creation, spin-off creation or other company growth.
Maturity level detalis: 
1- MASK-Allergy Diary is freely available in 15 EU countries and will be available before the end of the year in over 23 countries (globally). 2- The companion App for physicians and pharmacists will be released at the end of the year. 3- The Clinical Decision Support System will also be released...
Time of impact: 
Medium impact – e.g. shortly beyond the pilot project period
Kind of impact: 
Better quality of life (societal)
Aspects time of impact: 
1- The first pilot study has been analyzed (and submitted for publication (see paper 6 enclosed). 2- Jobs have been created. 3- However, the most important expected impact is on work productivity. Allergic rhinitis affect approximately 25% of the population. Respiratory and allergic conditions...
Transferability level: 
The innovative practice has been transferred in other locations or regions or national scale in the same country
Transferability details: 
The practice is developed by the ARIA (Allergic Rhinitis and its Impact on Asthma) working group which is established in 72 countries (25 EU countries) and is a major practice of AIRWAYS ICPs (Action Plan B3, EIP on AHA, 1 & 2). Thus, it is immediately deployed globally by the ARIA group with...
Initiative
Type of Practice: 
Good practice
Stakeholders concerned: 
Hospitals
Primary care centres
Specialised physicians
General practioners
Pharmacists
Nurses
Informal caregivers
Private companies
Micro-sized industry
Small-sized industry
Medium-sized industry
Research centres
Academia
NGOs
International/European public authorities
National public authorities , WHO
Regional public authorities
Local public authorities
Advocacy organisations patients/users
Advocacy organisations physicians
Advocacy organisations nurses
Advocacy organisations others
Other, please specify
citizens, patients with allergic rhinitis
Reach of initiative: 
> 100,000
Age group: 
< 18
18 – 49
50 - 64
65 - 79
80+
Baseline information: 
Over 5,000 users are recorded in a central database and first analyses show that MASK Allergy Diary can discriminate according to phenotype of allergic diseases and can monitor work and daily life impairment in those with AR. The results suggest novel concepts and research questions in AR that may...
Source of funding: 
Private funding